PEOPLE - Changes at Cygnus in the US:
This article was originally published in Clinica
Executive Summary
Cygnus in the US has announced that Gregory Lawless has resigned as president, CEO and director to pursue other interests. He is succeeded by John Hodgman, who was previously president of the group's Cygnus Diagnostics subsidiary. In addition, Andre Marion, a Cygnus director, has been elected vice-chairman. The company is developing non-invasive glucose monitoring and drug delivery systems. A distribution agreement with Becton Dickinson for the glucose monitoring system, GlucoWatch, was ended in March.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.